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Introduction:Hematopoietic stem cell (HSC)migration is essential
for peripheral blood HSC collection. Sympathetic signaling regu-
lates HSC egress from bone marrow. Ablation of adrenergic trans-
mission in animal models indicates that norepinephrine (NE)
controls G-CSF-induced HSC mobilization (Cell 2006). b adrener-
gic agonists and antagonists enhance and reduce HSC mobilization,
respectively. We prospectively studied catecholamines and the effi-
ciency of HSC collection in patients (pts) with AL amyloidosis un-
dergoing G-CSF mobilization prior to high dose melphalan and
HSC rescue on a phase II study.
Methods: 24h urine samples were analyzed for epinephrine (EPI),
NE and dopamine (DA) excretion before G-CSF administration
and after HSC collection was completed. Statistics included Spear-
man rank coefficient (r), Wilcoxon rank sum and Signed rank tests.
Results: In 39 pts median (med) CD34 cells collected was 8.3 x 106/
kg (IQR 5,12.3) in a med of 2 (IQR 2,3) collections. The med CD34
cells infused on day 0 was 4.7 x 106/kg (IQR 3.8, 6) and time to neu-
trophil engraftment (ANC. 500 x 2 days) was 9 days (IQR 9, 11).
Baseline urinary excretion of EPI and DA correlated with total
CD34 cells collected (r5 0.33, P5 0.005; r5 0.47, P5 0.05, respec-
tively). An optimal collection defined as 5 x 106 CD34 cells/kg in 2
collections was achieved by 25/39 pts and was associated with higher
baseline EPI (7 vs 4mcg/24h, P5 0.02) andDA (220 vs 156mcg/24h,
P5 0.05) but not NE. Only DA significantly changed from baseline
to after HSC collection (P #0.0001).
Conclusion: Sympathetic signals regulate HSC egress from their
niche, and we found baseline EPI and DA excretion are associated
with greater and more efficiently collected HSCs following G-CSF
in pts with AL amyloidosis. In mouse models G-CSF mobilization
requires peripheral adrenergic signals and reduces NE in bone
(Cell 2006). Reduced DA excretion following G-CSF in our study
may indicate that circulating catecholamines serve as markers for
overall sympathetic tone and could possibly predict mobilization ef-
ficiency in humans. These data support other evidence that DA plays
a role in progenitor migration (Nat Immunol. 2007) and indicates
that DA is important inG-CSFmobilization in pts with AL amyloid-
osis. Modulation of the sympathetic system to enhance HSC mobi-
lization and the use of catecholamine values to guide clinicians with
respect to the need for plerixafor or chemo-mobilization should be
explored.132
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Background: Limited therapeutic options exist for patients with
multiple myeloma (MM) relapsing after initial autologous hemato-
poietic stem cell transplantation (HSCT). A second autologous
HSCT using a different conditioning regimen may provide long-
term disease control. We report the pharmacokinetics and safety
of daily intravenous (IV) busulfan (Bu) conditioning given with bor-
tezomib for autologous HSCT from a multicenter, prospective
Phase 2 study.
Methods: 30 patients with relapsed MM who had a first autologous
HSCT $1 year prior to the planned HSCT were enrolled from
eleven centers in the US and Canada. Patients received a test dose
of IV Bu (0.8 mg/kg) over 2 hours between Days -12 and -9 prior
to HSCT. Blood samples were drawn for pharmacokinetic (PK)
analysis and Bu exposure was determined as area under the concen-
tration-time curve (AUC). Individualized Bu PK-directed dosing for
the conditioning regimen was recommended to achieve a total regi-
men AUC of 20,000 mM$min. IV Bu was administered over 3 hours
once daily from Day -5 to Day -2. Confirmatory PK analysis was
conducted in all patients on Day -5. Bu doses were adjusted on
Days -3 and -2, if needed. Bortezomib (1.3 mg/m2 QD) was admin-
istered as an IV bolus injection on Day -1.
Results: PK testing with 0.8 mg/kg of IV Bu dose revealed that
40.0% (n 5 12/30) of patients had doses outside the expected range
(1,250 mM$min +/- 20%). PK-directed daily Bu dose on the first day
of conditioning (Day -5) ranged between 1.99 and 4.73 mg/kg (94.6
and 213.4 mg/m2). Subsequent dosing based on test PK resulted in
93.3% of patients (n 5 28/30) falling within the target range
(AUC, 20,000 mM$min +/-20%), underscoring the utility of test
PK in achieving optimal dosing during conditioning.Mean Bu clear-
ance for test dose and on Day -5 were comparable, 3.03 and 2.93 ml/
min/kg, respectively. Two patients (6.7%) needed dose reduction on
Days -3 and -2. No instances of VOD, seizure, or worsening neurop-
athy have been reported to date. Grade 3 or higher stomatitis was ob-
served in 23% of patients (n5 7/30). One death occurred on Day 30
after transplant in a patient with Parkinsonism who died of pulmo-
nary complications.
Conclusion: Pre-transplant test dose PK analysis allows accurate
targeting of IV busulfan dosing in more than 90% of patients. The
conditioning regimen of bortezomib and IV busulfan with PK-di-
rected dose optimization is well-tolerated in patients with relapsed
MM who undergo second autologous HSCT.133
STEM CELL MOBILIZATION FAILURES SALVAGED WITH PLERIXAFOR:
LONG TERM FOLLOW UP OF ENGRAFTMENT AND OUTCOMES
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We enrolled 49 pts in a compassionate use protocol to mobilize
stem cells(SC) for pts who failed a mobilization attempt. Pts received
0.24 mg/kg of Plerixafor (P) sq 9 -11 hrs prior to apheresis in addi-
tion to BID GCSF. Table 1 shows pt demographics. Using P and
GCSF,$ 2.5 x 106 CD34+ cells/Kg were collected in 33 pts (67%).
Table.
Patient Demographics ResultsMedian Age 64 (23-74) years
DiagnosisNon Hodgkin Lymphoma 27 Pts ( 55%)
Multiple Myeloma 17 Pts (35%)
Hodgkin Lymphoma 5 Pts (10%)# of Previous mobilization Attempts
1 37 Pts (76%)
$ 2 12 Pts (24%)
